<DOC>
	<DOCNO>NCT00919035</DOCNO>
	<brief_summary>This single institution , open label , phase II study androgen-independent prostate cancer patient chemotherapy-naïve . Patients receive Torisel® 25 mg weekly . Treatment continue disease progression , patient 's withdrawal , unacceptable toxicity investigator 's discretion .</brief_summary>
	<brief_title>Single Agent Temsirolimus ( Torisel® ) Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients</brief_title>
	<detailed_description>This open label phase II study conduct patient androgen-independent castration-resistant prostate cancer receive systemic chemotherapy . Investigational therapy vaccine , immunotherapy , oral target agent NOT consider chemotherapy . Prior use steroid exclusion criterion . Patients meet inclusion criterion allow participate . Enrolled patient receive single agent Torisel® 25 mg weekly . Every 4 week therapy constitute one cycle treatment . Patients continue therapy voluntary withdrawal , toxicity , progression , investigator 's discretion . Patients follow 3 year discontinuation Torisel® . Patients allow receive intravenous oral bisphosphonates bone metastasis advise continue androgen blockade study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age 18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Documented prostate cancer regardless Gleason score 5 . Patients consider hormone refractory castrationresistant . They must fail LHRH analogue , antiandrogen withdrawal trial . Failure confirm increase PSA value 10 % value immediately . 6 . Patients must measurable disease either biochemically ( use PSA ) and/or use Response Evaluation Criteria Solid Tumors ( RECIST ) criteria visceral organ involvement and/or bone disease . If disease follow scan PSA value least 5 ng per milliliter need present baseline evaluate PSA response . 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 2 less . 8 . Adequate liver function test ALT/AST &lt; 3x normal , total bilirubin 1.5 less , adequate renal function measure creatinine 2.0 mg/dl less . Alkaline phosphatase value never exclusion criterion deem related bone metastasis . 9 . Patients need adequate bone marrow function . absolute neutrophil count ( ANC ) 1000 , Hgb 9.0 g/dl , Platelets 100,000 . If cause affect plts count autoimmune disorder , patient allow study . Patients inadequate bone marrow function deem related bone marrow involvement prostate cancer ( cytopenia due extensive marrow infiltration prostate cancer ) allow investigator 's discretion . 10 . Patients malignancy allow long evidence malignancy present entry time , 3 year since treatment disorder complete . Patients nonmelanoma skin cancer allow participate study . 11 . Investigational therapy vaccine , immunotherapy , oral target agent allow study long last exposure 4 week prior study entry . These agent consider exclusion criterion consider standard chemotherapy . 12 . Patients know bone metastasis allow receive intravenous bisphosphonates aredia zometa . Patients oral bisphosphonates also allow . 13 . All study participant encourage continue androgen deprivation LHRH analogue . 14 . Patients must agree use latex condom sexual contact female childbearing potential , even successful vasectomy despite fact androgen deprivation . 15 . Last treatment prostate cancer least 4 week ago 1 . Prior systemic chemotherapy castration Resistant Prostate Cancer ( CRPC ) 2 . Prior exposure temsirolimus ( TEM ) 3 . Known HIV positive status infectious hepatitis , type A , B , C. 4 . Known brain metastasis . 5 . Steroids allow concomitantly ONLY IF take another chronic medical condition ( Such chronic obstructive pulmonary disease , Multiple sclerosis…etc ) 6 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject sign understanding informed consent form . 7 . Any condition , include presence laboratory abnormality , place subject unacceptable risk participate study confound ability interpret data study . 8 . Use experimental drug therapy within 28 day baseline .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>androgen-independent prostate cancer ( AIPC ) Prostate Cancer</keyword>
</DOC>